๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed

โœ Scribed by A. Ladopoulou; C. Kroupis; I. Konstantopoulou; L. Ioannidou-Mouzaka; A.C. Schofield; A. Pantazidis; S. Armaou; I. Tsiagas; E. Lianidou; E. Efstathiou; C. Tsionou; C. Panopoulos; M. Mihalatos; G. Nasioulas; D. Skarlos; N.E. Haites; G. Fountzilas; N. Pandis; D. Yannoukakos


Book ID
117467239
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
311 KB
Volume
185
Category
Article
ISSN
0304-3835

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Novel germline mutations in the BRCA1 an
โœ Mani T. Valarmathi; Meenakshi Sawhney; Suryanarayana S. V. Deo; Nootan K. Shukla ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 97 KB ๐Ÿ‘ 2 views

The two major hereditary breast/ovarian cancer predisposition tumor suppressor genes, BRCA1 and BRCA2 that perform apparently generic cellular functions nonetheless cause tissue-specific syndromes in the human population when they are altered, or mutated in the germline. However, little is known abo

Novel germline BRCA1 and BRCA2 mutations
โœ Eva Machackova; Jiri Damborsky; Dalibor Valik; Lenka Foretova ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 3 views

## Communicated by Mark H. Paalman Germline mutations in breast cancer susceptibility genes, BRCA1 and BRCA2, are responsible for a substantial proportion of high-risk breast and breast/ovarian cancer families. To characterize the spectrum of BRCA1 and BRCA2 mutations, we screened Czech families w

BRCA1 and BRCA2 mutations in women with
โœ Lenka Foretova; Eva Machackova; Marie Navratilova; Hana Pavlu; Marcela Hruba; Mi ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 45 KB ๐Ÿ‘ 2 views

Germline mutations in BRCA1 and BRCA2 account for majority of hereditary breast and ovarian cancer. The complete coding sequence analysis of both genes was carried out in 197 breast/ovarian cancer patients from high-risk families and 53 patients with sporadic breast/ovarian cancer. In summary, 59 mu